Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00925756 · ClinicalTrials.gov registry record · Phase 4
CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery
A Phase 4 study, sponsored by University of California, San Diego.
- Completed
- Registry status
- Phase 4
- Development phase
- 32
- Enrollment target
NCT00925756 is a Phase 4 study that has completed, run by University of California, San Diego. The registered enrollment target is 32 participants.
The verdict
NCT00925756, a Phase 4 study, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 32 participants
- Enrollment target
Study Summary
CCTG 590 is a open-label study to evaluate the impact of therapy intensification with Maraviroc (MVC) (a CCR5 inhibitor) to a stable suppressive HIV antiretroviral regimen on the rate of CD4+ T-cell recovery and gene expression profiles. Patients on a stable first-line HIV regimen with continued viral suppression and sub-optimal CD4+ T-cell counts will be eligible for this study. Those who are found to be eligible will have MVC (dose-adjusted to background HIV regimen) added to their current HIV regimen for 24 weeks. After the 24 week intensification, the MVC will be discontinued, the original antiretroviral regimen will be continued and the subjects will be followed for an additional 12 weeks. The investigators hypothesize that MVC will improve the rate of CD4 recovery. This improved CD4 recovery will be associated with favorable changes in gene expression profiles of genes involved with CD4 maintenance and circulation.
Interventions
- DRUG Maraviroc
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2008-10-20 |
| Est. Completion | 2014-04-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00925756
The ClinicalTrials.gov registry entry for NCT00925756 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Maraviroc is the first listed.
NCT00925756 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00925756 about?
NCT00925756 is a clinical study titled "CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery". CCTG 590 is a open-label study to evaluate the impact of therapy intensification with Maraviroc (MVC) (a CCR5 inhibitor) to a stable suppressive HIV antiretroviral regimen on the rate of CD4+ T-cell recovery and gene expression profiles. Patients on a stable first-line HIV regimen with continued vir...
What is the current status of trial NCT00925756?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 32 participants. The study started on 2008-10-20. Estimated completion is 2014-04-11.
What interventions are being tested in trial NCT00925756?
The interventions under investigation include: Maraviroc (DRUG).
Who is sponsoring clinical trial NCT00925756?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.